# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27....
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE: CVM), a cancer immunotherapy company, today announced t...
Multikine, a true first-line cancer immunotherapy, cut the 5-year risk of death by half compared to control in its target popul...
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company ...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to ap...